A TMB-high cutoff of 10 mutations per megabase doesn't predict immunotherapy responses universally well across cancer types, according to a paper published in JAMA Oncology.
The deal centers around Metabolon's platform for identifying pharmacodynamic, efficacy, and response biomarkers and tracking changes in biological pathways.
The test, which was developed by researchers at the Cleveland Clinic and the University of Alabama, looks for RNA molecules in urine that indicate rejection.
Researchers linked chromatin interactions, super-interactive promoters, and other regulatory features to specific cell types in the developing brain cortex.
The company will apply its single-cell RNA-seq analytics technology to three distinct cohorts in pursuit of new drug targets for inflammatory bowel disease.
Researchers found that 61 percent of patients they analyzed carried germline pathogenic or likely pathogenic variants in candidate cancer predisposition genes.
A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.
Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.
